Akèy › Kansè Poumon ki pa ti selil › North Carolina

Etid klinik pou Kansè Poumon ki pa ti selil nan North Carolina

79 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan North Carolina.

Vil nan North Carolina

Tèks ofisyèl etid la (Anglè)

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

FirstHealth of the Carolinas- Speciality Center /ID# 272924, Pinehurst

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT06568939

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07388524

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Cone Health MedCenter Asheboro, Asheboro
Cone Health Cancer Center at Alamance Regional, Burlington
Wake Forest University at Clemmons, Clemmons
ak 8 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT04267848

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Carolina Cancer Research Center, Wilson

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Duke University, Durham

Ap rekriteFaz 1/2

Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Novant Health Weisiger Cancer Insititute ( Site 0266), Charlotte
Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06623422

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #12, Durham

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Charles George VA Medical Center ( Site 3233), Asheville
UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill
WakeMed Raleigh Campus ( Site 3214), Raleigh

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07513376

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

WakeMed Raleigh Campus ( Site 0144), Raleigh

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07554339

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Duke Cancer Center Cary, Cary
Durham VA Medical Center, Durham
Duke University Medical Center, Durham
ak 2 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Novant Health Pharmacy Oncology Specialists, Winston-Salem

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Novant Health Pharmacy Oncology Specialists, Winston-Salem

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Carolinas Medical Center, Charlotte
Duke Cancer Center, Durham

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06765109

A Study of PHN-012 in Patients With Advanced Solid Tumors

PHN-012-001 Site, Durham

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07127874

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Levine Cancer Institute, Charlotte
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04253964

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Messino Cancer Centers Asheville, Asheville
Duke University Medical Center, Durham
FirstHealth Cancer Center, Pinehurst

Ap rekriteFaz 3

Laj 18 a 100 · Tout sèks · Mizajou Sep 25, 2026 · NCT05920356

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

FirstHealth Cancer Center, Pinehurst
FirstHealth Moore Regional Hospital, Pinehurst
Carolina Cancer Research Center, Wilson

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07222566

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of North Carolina at Chapel Hill, Chapel Hill
FirstHealth of the Carolinas, Pinehurst

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667908

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Atrium Health, Charlotte
Regional Medical Oncology Center, Wilson
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Brody School of Medicine at East Carolina University, Greenville
ECU Health Medical Center, Greenville
Carolina Cancer Research Center, Wilson

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

WakeMed Raleigh Campus, Raleigh

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598

Pan-tumor MRD Study

Carolina Oncology Specialists, Charlotte
Southeastern Medical Oncology Center (SMOC), Goldsboro
Regional Medical Oncology Center, Wilson

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Greenville
Research Site, Salisbury

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06357533

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

East Carolina University, Greenville

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06561386

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0624, Asheville

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06875310

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Atrium Health Levine Cancer, Charlotte
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT05696782

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06712316

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Duke Cancer Center Durham, Durham

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07488676

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

FirstHealth of the Carolinas, Inc., Pinehurst

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06745882

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Wilson

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06692738

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Carolina Biooncology Institute, Huntersville

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Chapel Hill
Clinical Study Site, Durham
Clinical Study Site, Pinehurst

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Levine Cancer Institute, Charlotte
Durham VA Health Care System, Durham

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07195695

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Duke University School of Medicine, Durham

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Duke University Medical Center, Durham

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596

Effects of Infusion Timing on Treatment Response in Solid Tumors

University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07630168

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

FirstHealth Cancer Center, Pinehurst
Carolina Cancer Research Center, Wilson

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06899126

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.